FDA semaglutide coverage for business development, investment, and market access teams
Medicare GLP-1 coverage 2026: Bridge program starts July 1
US FDA Proposes New Regulations on Weight-Loss Drug Compounding
Sunlight GLP-1 2026: FDA's Decision on Compounded Semaglutide
altRx GLP-1 Review 2026: FDA Updates on Semaglutide
Novo Nordisk Reports Record Q1 Revenue Driven by Wegovy and Ozempic Demand
Novo Nordisk's Oral Ozempic Becomes First FDA-Approved Pill GLP-1 for Type 2 Diabetes with Cardiovascular Protection
Alzheimer's Clinical Trial Failures: Insights from Semaglutide & Posdinemab FDA Trials
Alzheimer's Clinical Trial Failures: Novo Nordisk's Semaglutide Phase 3 Outcome & Market Impact
GLP-1 Eating Disorder Risk: What You Need to Know
FDA Labeling Changes for Oral Semaglutide: Cardiovascular Risk Insights
Novo Nordisk's Oral Semaglutide Shows Promise as First GLP-1 Therapy for Children with Type 2 Diabetes
FDA Approves Semaglutide Trial Update for Obesity Treatment